Immediately thereafter, the phase III JAVELIN Gastric 100 study [34] compared the efficacy of avelumab and chemotherapy as first-line maintenance therapy in patients with HER2-negative gastric cancer, respectively. Here, ERBB2 is linked to gastric cancer.